Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the ``Registro Italiano LMC \& Campus CML{''} BLOOD 2020
Hematopoietic Stem Cell Transplantation in Myelofibrosis: The Experience of Three University Transplant Centres in Rome BONE MARROW TRANSPLANTATION 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance LEUKEMIA & LYMPHOMA 2020
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors INTERNATIONAL JOURNAL OF CARDIOLOGY 2020
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis CANCER 2020
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review BONE MARROW TRANSPLANTATION 2020
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice ANNALS OF HEMATOLOGY 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinib BRITISH JOURNAL OF HAEMATOLOGY 2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients ANNALS OF HEMATOLOGY 2020
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview LEUKEMIA 2019
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial LEUKEMIA 2019
A 35 year single center transplant experience in chronic myeloid leukemia BONE MARROW TRANSPLANTATION 2019
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia EXPERT REVIEW OF HEMATOLOGY 2019
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia THERAPEUTIC ADVANCES IN HEMATOLOGY 2019
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib ANNALS OF HEMATOLOGY 2019
Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients JOURNAL OF CLINICAL ONCOLOGY 2019
Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations JOURNAL OF CLINICAL ONCOLOGY 2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors HEMATOLOGICAL ONCOLOGY 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice ANNALS OF HEMATOLOGY 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice ANNALS OF HEMATOLOGY 2019

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma